Clinical Trials
132 trialsCabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
RABBIT
University of Arizona
DOTATOC PET/CT for Imaging NET Patients
British Columbia Cancer Agency
Cancer and Blood Pressure Management, CARISMA Study
Eastern Cooperative Oncology Group
Lumed
University Hospital, Basel, Switzerland
LIBRETTO-321
Eli Lilly and Company
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
Sanofi
LIBRETTO-001
Eli Lilly and Company
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
Shanghai Jiao Tong University School of Medicine
Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer
M.D. Anderson Cancer Center
Natural History Study of Children and Adults With Medullary Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
LIBRETTO-531
Eli Lilly and Company
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
M.D. Anderson Cancer Center
CAST-MTC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Patient Decision Aid in Supporting Decision-Making About When to Start or Stop New Drugs, Join Clinical Trials, or Continue Active Surveillance in Patients With Medullary Thyroid Cancer and Their Caregivers
M.D. Anderson Cancer Center
LIBRETTO-121
Eli Lilly and Company
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
University of Southern California
CMTpostopFDOPA
Institut Claudius Regaud
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
Sanofi
An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer
Sanofi
EXAMINER
Exelixis
Research on the Application of 68Ga-DOTA-CCK-FS PET/CT in MTC
Peking Union Medical College Hospital
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
GFRα4 CAR T Cells in MTC Patients
University of Pennsylvania
A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
MIMETIC
University Medical Center Groningen
ARROW
Hoffmann-La Roche
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
Instituto do Cancer do Estado de São Paulo
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
PEPATI-MN-2024
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Eli Lilly and Company
MYELO
Aristotle University Of Thessaloniki
Caprelsa104
Sanofi
MOLTHY
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Universidad Nacional Autonoma de Mexico
Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid Carcinoma
First Affiliated Hospital of Fujian Medical University
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
NantCell, Inc.
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
Turning Point Therapeutics, Inc.
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer
M.D. Anderson Cancer Center
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer
National Cancer Institute (NCI)
DSR-MTC
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
A Study of TY-1091 in Patients With Advanced Solid Tumors
TYK Medicines, Inc
AcceleRET-MTC
Hoffmann-La Roche
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications
University College, London